LINCOLN PHARMACEUTICALS
|
LINCOLN PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 46.58 | 36.40 | 34.63 | 31.08 | 25.72 |
| CEPS(Rs) | 51.89 | 40.97 | 38.66 | 34.85 | 29.40 |
| DPS(Rs) | 1.80 | 1.50 | 1.50 | 1.50 | 1.50 |
| Book NAV/Share(Rs) | 295.98 | 250.86 | 216.12 | 182.92 | 156.54 |
| Tax Rate(%) | 23.67 | 27.45 | 27.71 | 25.65 | 23.45 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.57 | 16.68 | 19.23 | 19.88 | 16.40 |
| EBIT Margin(%) | 20.51 | 19.17 | 19.61 | 19.45 | 17.33 |
| Pre Tax Margin(%) | 20.27 | 18.79 | 19.32 | 19.09 | 16.83 |
| PAT Margin (%) | 15.47 | 13.63 | 13.97 | 14.19 | 12.88 |
| Cash Profit Margin (%) | 17.23 | 15.35 | 15.60 | 15.92 | 14.71 |
| Performance Ratios | |||||
| ROA(%) | 13.70 | 12.24 | 13.31 | 13.48 | 12.33 |
| ROE(%) | 17.04 | 15.59 | 17.35 | 18.32 | 17.67 |
| ROCE(%) | 22.53 | 21.82 | 24.29 | 24.90 | 22.30 |
| Asset Turnover(x) | 0.89 | 0.90 | 0.95 | 0.95 | 0.96 |
| Sales/Fixed Asset(x) | 2.78 | 2.90 | 3.17 | 3.04 | 2.81 |
| Working Capital/Sales(x) | 1.70 | 1.81 | 1.89 | 1.88 | 2.19 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.36 | 0.34 | 0.32 | 0.33 | 0.36 |
| Receivable days | 90.22 | 86.09 | 84.27 | 89.34 | 102.22 |
| Inventory Days | 44.55 | 48.72 | 43.86 | 39.12 | 38.19 |
| Payable days | 110.27 | 124.63 | 138.44 | 126.82 | 125.84 |
| Valuation Parameters | |||||
| PER(x) | 12.57 | 9.31 | 8.98 | 7.23 | 5.20 |
| PCE(x) | 11.28 | 8.27 | 8.04 | 6.45 | 4.55 |
| Price/Book(x) | 1.98 | 1.35 | 1.44 | 1.23 | 0.85 |
| Yield(%) | 0.31 | 0.44 | 0.48 | 0.67 | 1.12 |
| EV/Net Sales(x) | 2.00 | 1.27 | 1.28 | 1.03 | 0.67 |
| EV/Core EBITDA(x) | 8.63 | 5.79 | 5.75 | 4.70 | 3.37 |
| EV/EBIT(x) | 9.38 | 6.30 | 6.23 | 5.12 | 3.73 |
| EV/CE(x) | 1.95 | 1.28 | 1.09 | 0.90 | 0.59 |
| M Cap / Sales | 2.02 | 1.33 | 1.32 | 1.06 | 0.69 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.76 | 8.09 | 11.30 | 9.75 | 5.56 |
| Core EBITDA Growth(%) | 20.29 | 5.88 | 13.61 | 21.24 | 5.09 |
| EBIT Growth(%) | 20.68 | 5.26 | 14.20 | 23.15 | 4.62 |
| PAT Growth(%) | 27.99 | 5.11 | 11.41 | 20.95 | 5.60 |
| EPS Growth(%) | 27.99 | 5.11 | 11.41 | 20.84 | 5.60 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | 0.02 |
| Current Ratio(x) | 4.02 | 4.07 | 3.37 | 3.46 | 3.27 |
| Quick Ratio(x) | 3.36 | 3.34 | 2.71 | 2.97 | 2.68 |
| Interest Cover(x) | 84.45 | 50.50 | 67.11 | 54.61 | 34.32 |
| Total Debt/Mcap(x) | - | - | - | - | 0.02 |
Compare Financial Ratios of peers of LINCOLN PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LINCOLN PHARMACEUTICALS | ₹1,569.8 Cr | -3.8% | 24.7% | 31.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹441,838.0 Cr | 1% | 4.6% | 47.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,107.0 Cr | 1% | -3.2% | 59.3% | Stock Analytics | |
| CIPLA | ₹120,270.0 Cr | -1.1% | -0.3% | 20.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹113,077.0 Cr | 2.2% | 12.1% | 21.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | -2.7% | 0.8% | 43.8% | Stock Analytics | |
LINCOLN PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LINCOLN PHARMACEUTICALS | -3.8% |
24.7% |
31.4% |
| SENSEX | -2.1% |
-2% |
11.3% |
You may also like the below Video Courses
